L&K Biomed Ltd. (KOSDAQ:156100)
South Korea · Delayed Price · Currency is KRW 13,730
-910 (-6.22%)
At close: Feb 6, 2026
L&K Biomed Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 40,335 | 36,092 | 29,905 | 19,767 | 15,373 | 19,356 |
Other Revenue | 0 | - | -0 | -0 | -0 | - |
| 40,335 | 36,092 | 29,905 | 19,767 | 15,373 | 19,356 | |
Revenue Growth (YoY) | 21.55% | 20.69% | 51.28% | 28.59% | -20.58% | -27.16% |
Cost of Revenue | 7,116 | 5,950 | 4,227 | 4,975 | 8,019 | 5,899 |
Gross Profit | 33,219 | 30,142 | 25,678 | 14,792 | 7,354 | 13,457 |
Selling, General & Admin | 25,269 | 22,201 | 20,967 | 24,261 | 19,647 | 13,696 |
Research & Development | 2,685 | 2,053 | 1,329 | 1,369 | 1,358 | 977.97 |
Amortization of Goodwill & Intangibles | 57.08 | 14.9 | 86.26 | 46.82 | 146.24 | 644.97 |
Operating Expenses | 30,736 | 27,064 | 23,644 | 27,530 | 22,634 | 17,315 |
Operating Income | 2,483 | 3,078 | 2,034 | -12,738 | -15,280 | -3,859 |
Interest Expense | -3,296 | -2,681 | -2,002 | -2,206 | -1,380 | -1,145 |
Interest & Investment Income | 536.94 | 589.61 | 384.99 | 219.84 | 107.61 | 127.55 |
Earnings From Equity Investments | - | -300 | -1,172 | -1,199 | -556.16 | -420.88 |
Currency Exchange Gain (Loss) | 3,689 | 7,560 | 740.73 | 1,961 | 2,301 | -1,707 |
Other Non Operating Income (Expenses) | 2,451 | 1,621 | -330.56 | -2,027 | 4,630 | 639.47 |
EBT Excluding Unusual Items | 5,864 | 9,866 | -343.96 | -15,989 | -10,178 | -6,365 |
Gain (Loss) on Sale of Investments | 63.27 | 75.14 | 49.41 | - | 1,684 | - |
Gain (Loss) on Sale of Assets | 131.47 | 254.5 | 16.24 | -65.73 | 220.44 | -519.34 |
Asset Writedown | - | - | -16.8 | -243.71 | -623.87 | -2,355 |
Other Unusual Items | -237.36 | -380.94 | -6,173 | - | - | - |
Pretax Income | 5,822 | 9,815 | -6,468 | -16,299 | -8,897 | -9,239 |
Income Tax Expense | 406.29 | 663.59 | -1,229 | -65.76 | 4,749 | 1,433 |
Earnings From Continuing Operations | 5,415 | 9,151 | -5,239 | -16,233 | -13,646 | -10,672 |
Minority Interest in Earnings | 423.16 | 591.77 | 3,372 | 2,608 | 3,978 | -43.26 |
Net Income | 5,839 | 9,743 | -1,867 | -13,625 | -9,669 | -10,715 |
Net Income to Common | 5,839 | 9,743 | -1,867 | -13,625 | -9,669 | -10,715 |
Shares Outstanding (Basic) | 20 | 20 | 16 | 13 | 13 | 12 |
Shares Outstanding (Diluted) | 22 | 22 | 16 | 13 | 13 | 12 |
Shares Change (YoY) | 8.24% | 32.67% | 21.04% | 0.07% | 12.57% | 14.15% |
EPS (Basic) | 291.69 | 488.71 | -115.17 | -1017.14 | -722.29 | -901.11 |
EPS (Diluted) | 265.47 | 448.22 | -115.17 | -1017.14 | -722.29 | -901.11 |
Free Cash Flow | -13,361 | -8,015 | -3,417 | -6,684 | -10,501 | -2,721 |
Free Cash Flow Per Share | -618.83 | -372.60 | -210.77 | -498.99 | -784.49 | -228.82 |
Gross Margin | 82.36% | 83.52% | 85.87% | 74.83% | 47.84% | 69.52% |
Operating Margin | 6.16% | 8.53% | 6.80% | -64.44% | -99.40% | -19.94% |
Profit Margin | 14.47% | 27.00% | -6.24% | -68.93% | -62.90% | -55.36% |
Free Cash Flow Margin | -33.12% | -22.21% | -11.43% | -33.81% | -68.31% | -14.06% |
EBITDA | 5,248 | 5,650 | 4,347 | -10,436 | -13,555 | -770.01 |
EBITDA Margin | 13.01% | 15.65% | 14.54% | -52.80% | -88.18% | -3.98% |
D&A For EBITDA | 2,765 | 2,572 | 2,313 | 2,302 | 1,725 | 3,089 |
EBIT | 2,483 | 3,078 | 2,034 | -12,738 | -15,280 | -3,859 |
EBIT Margin | 6.16% | 8.53% | 6.80% | -64.44% | -99.40% | -19.94% |
Effective Tax Rate | 6.98% | 6.76% | - | - | - | - |
Advertising Expenses | - | 227.72 | 130.35 | 176.7 | 178.07 | 68.79 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.